+44 115 7870500
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

Research & Candidate Selection

Expert advice and support for early-stage discovery programs seeking new treatments for drug addiction, psychiatric and neurological disorders, obesity and binge-eating disorder. All aspects of strategy, screening and project support management are performed with a strong focus on clinical success and regulatory approval.

  • Design innovative non-clinical studies, prepare experimental protocols, outsource and monitor projects, analyse and interpret data, and prepare regulatory-standard reports
  • Strategic assessments of therapeutic indications, including competition from current therapies, market opportunities and novel drug targets
  • Screening strategies with key ”Go/No Go” decision points
  • Long-term collaborations bringing our expertise into our clients’ research projects to facilitate and expedite the discovery and selection of drug candidates for clinical development
  • Guidance, design and management of non-clinical efficacy and safety testing to differentiate clients’ drug-candidates from the competitors
  • Early-stage abuse and dependence liability assessments to de-risk programs
  • Ensure FDA and EMA compliance for the design and conduct of studies

Our expertise

DevelRx’s consultants each has at least 25 years of experience in R&D managing programs at Boots Pharmaceuticals, Knoll Pharmaceuticals (BASF Pharma), and in RenaSci with a range of external biotech and pharmaceutical industry clients. We have initiated clinical development of drug-candidates and supported successful development and registration of 12 new drugs for the treatment of opiate withdrawal, ADHD, binge-eating disorder, schizophrenia, opiate-induced constipation, Parkinson’s disease, epilepsy, anaesthesia, obesity and Type 2 diabetes. As globally acknowledged experts in evaluating drug abuse risks, we provide a key service in de-risking early-stage projects in therapeutic indications where regulatory approval and controlled drug scheduling are major obstacles to commercial viability.

Therapeutic Areas

  • Risk assessments for abuse and dependence liability
  • Treatments for substance use disorders
  • Pain
  • Anaesthetics
  • ADHD
  • Epilepsy
  • Anxiety
  • Depression
  • Schizophrenia
  • Binge-eating disorder
  • Parkinson’s disease
  • Alzheimer’s disease
  • Obesity
  • Diabetes

Key publications

Heal D, Goddard S, Smith S, Cheetham S. Comparison of the physical dependence syndromes produced in rats by morphine and diazepam. J Pharmacol Toxicol Methods. 2019, 99:106595.

Heal D, Kulkarni R, Pinder L, Rowley H. Use of in vivo intracerebral microdialysis in rats to identify stimulant drugs of abuse. J Pharmacol Toxicol Methods. 2019, 99:106595.

Smith S, Holland S, Slade J, Hallam M, Heal D. Progressive ratio (PR) intravenous self-administration testing in rats to assess the relative reinforcing effects of a wide range of substances of abuse. J Pharmacol Toxicol Methods. 2019, 99:106595.

Vickers SP, Hackett D, Murray F, Hutson PH, Heal DJ. Effects of lisdexamfetamine in a rat model of binge-eating. J Psychopharmacol. 2015, 29:1290-1307.

Heal DJ, Gosden J, Smith SL. Dopamine reuptake transporter (DAT) "inverse agonism" - a novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacol. 2014, 87:19-40.

- Drug Development
- Registration
- Marketing

DevelRx Logo


Pennyfoot Street,





Cookie PolicyPrivacy PolicyTerms & Conditions

Registered in England and Wales

Company number: 12028847